Literature DB >> 22071625

MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Chang-Il Hwang1, Jinhyang Choi, Zongxiang Zhou, Andrea Flesken-Nikitin, Alexander Tarakhovsky, Alexander Yu Nikitin.   

Abstract

MET, a receptor protein tyrosine kinase activated by hepatocyte growth factor (HGF), is a crucial determinant of metastatic progression. Recently, we have identified p53 as an important regulator of MET-dependent cell motility and invasion. This regulation occurs via feedforward loop suppressing MET expression by miR-34-dependent and -independent mechanisms. Here, by using Dicer conditional knockout, we provide further evidence for microRNA-independent MET regulation by p53. Furthermore, we show that while MET levels increase immediately after p53 inactivation, mutant cells do not contain active phosphorylated MET and remain non-invasive for a long latency period at contrary to cell culture observations. Evaluation of mouse models of ovarian and prostate carcinogenesis indicates that formation of desmoplastic stroma, associated production of HGF by stromal cells and coinciding MET phosphorylation precede cancer invasion. Thus, initiation mutation of p53 is sufficient for preprogramming motile and invasive properties of epithelial cells, but the stromal reaction may represent a critical step for their manifestation during cancer progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22071625      PMCID: PMC3266114          DOI: 10.4161/cc.10.22.18294

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  76 in total

1.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

2.  Coevolution of cancer and stromal cellular responses.

Authors:  Laurie E Littlepage; Mikala Egeblad; Zena Werb
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

Review 3.  Canalization of development by microRNAs.

Authors:  Eran Hornstein; Noam Shomron
Journal:  Nat Genet       Date:  2006-06       Impact factor: 38.330

4.  Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer.

Authors:  Zongxiang Zhou; Andrea Flesken-Nikitin; David C Corney; Wei Wang; David W Goodrich; Pradip Roy-Burman; Alexander Yu Nikitin
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

5.  Frequent downregulation of miR-34 family in human ovarian cancers.

Authors:  David C Corney; Chang-Il Hwang; Andres Matoso; Markus Vogt; Andrea Flesken-Nikitin; Andrew K Godwin; Aparna A Kamat; Anil K Sood; Lora H Ellenson; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

6.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

7.  The impact of p53 protein core domain structural alteration on ovarian cancer survival.

Authors:  Stephen L Rose; Andrew D Robertson; Michael J Goodheart; Brian J Smith; Barry R DeYoung; Richard E Buller
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

Review 8.  Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Authors:  Paolo M Comoglio; Silvia Giordano; Livio Trusolino
Journal:  Nat Rev Drug Discov       Date:  2008-06       Impact factor: 84.694

9.  Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Authors:  Valery Tarasov; Peter Jung; Berlinda Verdoodt; Dmitri Lodygin; Alexey Epanchintsev; Antje Menssen; Gunter Meister; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

10.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

Authors:  L Naldini; K M Weidner; E Vigna; G Gaudino; A Bardelli; C Ponzetto; R P Narsimhan; G Hartmann; R Zarnegar; G K Michalopoulos
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  13 in total

1.  Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer.

Authors:  Heather Ann Brauer; Liza Makowski; Katherine A Hoadley; Patricia Casbas-Hernandez; Lindsay J Lang; Erick Romàn-Pèrez; Monica D'Arcy; Alex J Freemerman; Charles M Perou; Melissa A Troester
Journal:  Clin Cancer Res       Date:  2012-12-12       Impact factor: 12.531

2.  Emerging role of transcription factor-microRNA-target gene feed-forward loops in cancer.

Authors:  Qian Wu; Hua Qin; Qiu Zhao; Xing-Xing He
Journal:  Biomed Rep       Date:  2015-06-11

3.  Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells.

Authors:  R Mitchell Baldwin; Alan Morettin; Genevieve Paris; Isabelle Goulet; Jocelyn Côté
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

4.  Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53.

Authors:  Wen-Ting Liu; Ying-Ying Jing; Guo-feng Yu; Hong Chen; Zhi-peng Han; Dan-Dan Yu; Qing-Min Fan; Fei Ye; Rong Li; Lu Gao; Qiu-Dong Zhao; Meng-Chao Wu; Li-Xin Wei
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 5.  MicroRNAs: The Link between the Metabolic Syndrome and Oncogenesis.

Authors:  Adriana Fodor; Andrada Luciana Lazar; Cristina Buchman; Brandusa Tiperciuc; Olga Hilda Orasan; Angela Cozma
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

Review 6.  Recent discoveries in the cycling, growing and aging of the p53 field.

Authors:  James A McCubrey; Zoya N Demidenko
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

7.  MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11.

Authors:  Vinayakumar Siragam; Zina Jeyapalan Rutnam; Weining Yang; Ling Fang; Linlin Luo; Xiangling Yang; Minhui Li; Zhaoqun Deng; Jun Qian; Chun Peng; Burton B Yang
Journal:  Oncotarget       Date:  2012-11

Review 8.  The consequence of oncomorphic TP53 mutations in ovarian cancer.

Authors:  Pavla Brachova; Kristina W Thiel; Kimberly K Leslie
Journal:  Int J Mol Sci       Date:  2013-09-23       Impact factor: 5.923

9.  Mutation or loss of p53 differentially modifies TGFβ action in ovarian cancer.

Authors:  Eoghainín Ó hAinmhire; Suzanne M Quartuccio; Whay Cheng; Roshan A Ahmed; Shelby M King; Joanna E Burdette
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

10.  The role of EMMPRIN expression in ovarian epithelial carcinomas.

Authors:  Yang Zhao; Shuo Chen; Wen-feng Gou; Zhe-feng Niu; Shuang Zhao; Li-jun Xiao; Yasuo Takano; Hua-chuan Zheng
Journal:  Cell Cycle       Date:  2013-08-08       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.